SaNOtize
SaNOtize is a Vancouver-based pharmaceutical company commercializing nitric oxide-based therapeutics through its proprietary NORS platform, with a flagship nasal spray for respiratory infections sold across 20+ countries via regional distribution partners.
- Company typePrivate
- Founded2017
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What SaNOtize does
SaNOtize Research and Development Corp. is a Vancouver-based pharmaceutical company founded in 2017 by Dr. Chris Miller and Dr. Gilly Regev to commercialize nitric oxide (NO)-based therapeutics. The company developed a proprietary Nitric Oxide Releasing Solution (NORS) platform that stabilizes and delivers nitric oxide in localized, controlled doses, overcoming historical delivery constraints that required pressurized gas cylinders. The flagship product is a Nitric Oxide Nasal Spray (NONS) indicated for prevention and treatment of COVID-19 and upper respiratory infections, with Phase 3 trial data showing viral load reduction of approximately 95% within 24 hours and 99% within 48 hours. The product portfolio extends to topical formulations including sinusitis gels, foot cleansers for plantar warts and athlete's foot, onychomycosis treatments, and skin infection gels, all leveraging the same NORS chemistry.
SaNOtize operates a hybrid commercial model combining direct-to-consumer e-commerce (with 35,000+ customers reported converted) with physician-dispensed therapeutics and regional licensing partnerships. The nasal spray is sold under country-specific brand names through local commercialization partners: FabiSpray via Glenmark in India and broader Asia, VirX via Star Rich in Thailand, Enovid via DNR in Indonesia, and through pharmacy channels in Israel and Bahrain. A distribution agreement with Cytori covers Japan. Products are reportedly available in more than 20 countries worldwide. Revenue is generated through product sales and licensing arrangements, although specific figures are not publicly disclosed; the company has indicated it requires less than $10 million in additional capital to reach profitability.
The company has raised approximately $24 million in equity capital across multiple rounds, anchored by a $24 million Series B in August 2022 co-led by Horizons Ventures and OurCrowd with participation from Agricultural Bank of China International, supplemented by non-dilutive grants from the U.S. Department of Defence ($1.2 million for diabetic foot ulcer trials) and NRC-IRAP (CAD $400,000). Leadership transitioned in September 2023 when Steven Basta was appointed CEO, with founder Gilly Regev moving to a Chief Strategy and Innovation Officer role. The board includes Nobel laureate Ferid Murad and former Teva Global CFO Dan Suesskind. SaNOtize is currently expanding clinical evidence through the ECRAID-Prime Phase IIb trial in Europe (28 sites across 8 countries) and is evaluating NONS for sinusitis, signaling a pivot beyond the COVID-19-only narrative.
SaNOtize firmographics
Firmographics- Name
- SaNOtize
- Legal name
- SaNOtize Research and Development Corp.
- Website
- https://sanotize.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SaNOtize is a Vancouver-based pharmaceutical company commercializing nitric oxide-based therapeutics through its proprietary NORS platform, with a flagship nasal spray for respiratory infections sold across 20+ countries via regional distribution partners.
- Ownership category
- akta.pro rank
SaNOtize industry classification
Industry- Product category
- Antimicrobial Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
- akta.pro secondary industries
- Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)
Keywords
Where SaNOtize is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
SaNOtize business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Product Sales (DTC E-commerce): Direct-to-consumer sales of nitric oxide-based products through e-commerce channels, with 35,000+ customers converted. Products include nasal sprays, cleansers, and gel formulations.
- Physician-Dispensed Therapeutics: Commercial-stage sales through physician recommendation and dispensing model for consumer health products targeting common infections.
- Licensing and Commercialization Partnerships: Partnership with Glenmark for commercialization of NONS (FabiSpray) in India and Asian markets. Distribution agreements with Cytori for Japan market.
- Geographic Expansion: Products approved and available in more than 20 countries worldwide, generating revenue through regional commercial partnerships.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
SaNOtize product offering
Product offeringCore offering
SaNOtize develops and commercializes nitric oxide-based therapeutics using its proprietary Nitric Oxide Releasing Solution (NORS) platform, which stabilizes and delivers nitric oxide in precise topical doses for the treatment and prevention of viral, bacterial, and fungal infections. The company's flagship product is the Nitric Oxide Nasal Spray (NONS) sold under brand names Enovid (Israel/Bahrain), FabiSpray (India), and VirX (Thailand), with a broader portfolio of topical gels and cleansers targeting sinusitis, plantar warts, onychomycosis, athlete's foot, skin infections, and wound infections.
Product overview
SaNOtize is a pharmaceutical company that developed the Nitric Oxide Releasing Solution (NORS™) platform technology, enabling the delivery of nitric oxide as a targeted therapeutic antimicrobial. The core product is the Nitric Oxide Nasal Spray (NONS™), sold under brand names Enovid (Israel, Bahrain), FabiSpray® (India), and VirX (Thailand). The product portfolio extends beyond nasal sprays to include various topical formulations: gels for sinusitis and skin infections, foot cleansers for plantar warts and athlete's foot, and an onychomycosis gel for nail fungal infections. The company operates as a hybrid model combining physician sales with DTC e-commerce, with products available in more than 20 countries worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- NONS (Nitric Oxide Nasal Spray): Nitric Oxide Nasal Spray product for COVID-19 treatment and prevention
- Enovid
- FabiSpray
- VirX
- NORS (Nitric Oxide Releasing Solution)
Products and services
- Nitric Oxide Nasal Spray (NONS) Nitric oxide-releasing nasal spray sold under multiple brand names (Enovid in Israel/Bahrain, FabiSpray in India, VirX in Thailand) for the prevention and treatment of COVID-19 and other upper respiratory infections. Phase 3 data showed viral load reduction of more than 94% within 24 hours and more than 99% within 48 hours; 75% post-exposure risk reduction in a Thailand university study of 625 students; for adult consumers and physicians in approved markets.
- Nitric Oxide Releasing Gel (Sinusitis) Topical nitric oxide gel formulation under clinical development for the treatment of sinusitis, leveraging the proprietary NORS platform for localized antimicrobial delivery in the sinus cavity. Targeted at physicians and patients with chronic or recurrent sinusitis.
- Nitric Oxide Releasing Foot Cleanser
Quantifiable outcome
- Reduced viral load by >94% in first 24 hours and >99% by 48 hours in Phase 3 COVID-19 trial
- +3 more outcomes
Companies that use SaNOtize
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
SaNOtize technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
SaNOtize partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and regional.
- ECRAID-PrimecoreCollaboration in Europe's adaptive primary-care platform trial to evaluate NONS for respiratory infections. Phase IIb study spanning 28 sites across 8 European countries comparing NONS vs intranasal saline.
- Glenmark PharmaceuticalscoreCommercialization agreement for NONS (FabiSpray) in India and Asian markets. Glenmark obtained regulatory approval in India and launched the product commercially. Partnership includes peer-reviewed Lancet publication of Phase 3 results.
- CytoriregionalDistribution deal signed for NONS in Japan. Cytori plans to consult with PMDA for early approval of the therapeutic.
- DNR (Indonesia)regionalEnovid nose sanitizer launched in Indonesian market through DNR distribution partnership
- SWU (Srinakharinwirot University, Thailand)regionalClinical study collaboration with SWU in Thailand for VirX nasal spray evaluation. CEO Dr. Gilly Regev visited Thailand to collaborate.
- Star Rich (Thailand)regionalVirX nasal spray imported and sold in Thailand through Star Rich partnership. Clinical collaboration with SWU for study.
- SPIRE BioventuresregionalPartnership to expand Bay Area presence and accelerate growth through strategic advisory support
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
SaNOtize competitors and assessment
Company assessmentBroad incumbents
- Pfizer (Paxlovid): Global pharmaceutical leader with Paxlovid, the leading oral antiviral for COVID-19 treatment. Represents the dominant alternative therapeutic approach for SaNOtize's primary indication and a benchmark for global respiratory therapeutics commercialization.
- AstraZeneca: Global biopharmaceutical company with extensive respiratory therapeutics portfolio (including Evusheld for COVID-19 prevention). Former AstraZeneca Canada President Elaine Campbell serves on SaNOtize's board, reflecting the strategic adjacency in respiratory and infectious disease.
- Glenmark Pharmaceuticals: Indian multinational pharmaceutical company and SaNOtize's commercialization partner for FabiSpray in India and Asia. Overlapping respiratory therapeutics portfolio (inhalers, nasal sprays) and significant commercial reach that serves both as a partner and a competitive benchmark.
- Vir Biotechnology: Clinical-stage immunology company developing antiviral therapeutics including treatments for COVID-19 and respiratory infections. Comparable in therapeutic focus on infectious disease, particularly respiratory viral pathogens targeted by SaNOtize's NONS.
Emerging players
- Starpharma Holdings (VivaGel): Develops VivaGel, an antiviral/antibacterial nasal and topical product based on dendrimer technology. Comparable as a developer of locally-acting antimicrobial nasal/topical therapeutics with a platform approach and OTC consumer health positioning.
- Bovicor Pharmatech: Animal health company developing nitric oxide-based therapeutics, co-founded by SaNOtize co-founder Gilly Regev. Closely related through shared nitric oxide technology platform and overlapping scientific leadership.
- Bellerophon Therapeutics: Clinical-stage therapeutics company developing inhaled nitric oxide-based treatments for cardiopulmonary diseases. Comparable in the use of nitric oxide as a therapeutic modality and focus on respiratory/cardiovascular clinical applications.
Direct peers
- Nasus Pharma (Taffix): Israel-based company that developed Taffix, a nasal powder spray for COVID-19 prevention. Direct competitor in the nasal COVID-19 prevention category with overlapping target customer segments (consumers, travelers, front-line workers) and similar mechanism of topical nasal protection.
- Novan Inc. Clinical-stage pharmaceutical company developing nitric oxide-based therapeutics for dermatological and infectious disease indications. Most directly comparable to SaNOtize as both companies are built around proprietary nitric oxide delivery platforms targeting skin and mucosal infections.
- Mallinckrodt Pharmaceuticals (INOmax): Markets INOmax, the FDA-approved inhaled nitric oxide therapy. Comparable to SaNOtize in therapeutic modality (nitric oxide delivery) and clinical application (respiratory). SaNOtize's CEO Mikael Svensson previously led the INOmax launch across US and Europe, illustrating the strategic adjacency.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
SaNOtize social profiles
Digital presenceSaNOtize financial estimates
Financial estimateRevenue estimate
Valuation estimate
SaNOtize leadership team
Management profileNumber of profiles
Profiles10 records
SaNOtize funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SaNOtize M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SaNOtize
What does SaNOtize do?
SaNOtize develops and commercializes nitric oxide-based therapeutics using its proprietary Nitric Oxide Releasing Solution (NORS) platform, which stabilizes and delivers nitric oxide in precise topical doses for the treatment and prevention of viral, bacterial, and fungal infections. The company's flagship product is the Nitric Oxide Nasal Spray (NONS) sold under brand names Enovid (Israel/Bahrain), FabiSpray (India), and VirX (Thailand), with a broader portfolio of topical gels and cleansers targeting sinusitis, plantar warts, onychomycosis, athlete's foot, skin infections, and wound infections.
Is SaNOtize a public or private company?
SaNOtize is a private company. It is classified as venture growth investor backed and is currently operating.
When was SaNOtize founded?
SaNOtize was founded in 2017. It employs 11 to 50 people.
Where is SaNOtize based?
SaNOtize is headquartered in Vancouver, Canada, in the North America region.
How does SaNOtize make money?
Four revenue lines are on record. Product Sales (DTC E-commerce) is the primary driver. The others are physician-Dispensed Therapeutics, licensing and Commercialization Partnerships and geographic Expansion.
Who are SaNOtize's main competitors?
Broad incumbents on record are Pfizer (Paxlovid), AstraZeneca, Glenmark Pharmaceuticals and Vir Biotechnology. Emerging players are Starpharma Holdings (VivaGel), Bovicor Pharmatech and Bellerophon Therapeutics. Direct peers are Nasus Pharma (Taffix), Novan Inc. and Mallinckrodt Pharmaceuticals (INOmax).
Does SaNOtize have an API?
No public API is recorded for SaNOtize.
What industry is SaNOtize in?
SaNOtize's product category is Antimicrobial Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAIADAC, Allergy, Sinus & Respiratory (Non-Asthma). Its NAICS code is 325411 and its SIC code is 3841.